notícias

Cardiovascular diseases (CVDs) remain the world's leading cause of mortality. According to the World Health Organization (WHO), CVDs cause approximately 17.9 million deaths annually, many of which are directly related to thrombotic events such as acute coronary syndrome, deep vein thrombosis, and pulmonary embolism. Thrombosis—the pathological formation of blood clots that obstruct arteries and veins—underpins the majority of these life-threatening conditions.

For decades, the standard of care for thrombotic diseases has centered on anticoagulant therapies, most notably heparin and warfarin. However, these conventional agents come with significant limitations, including the risk of heparin-induced thrombocytopenia (HIT), unpredictable anticoagulant responses, and bleeding complications. In this context, hirudin—the natural anticoagulant secreted by medicinal leeches—has emerged as a scientifically validated alternative with unique pharmacological advantages.

Hirudin is a single-chain polypeptide of 65 amino acids with a molecular weight of approximately 7 kDa, stabilized by three intramolecular disulfide bridges. Discovered from the salivary glands of Hirudo medicinalis, hirudin is widely recognized as the most potent natural inhibitor of thrombin known to date.

The mechanism of hirudin is remarkably elegant. Unlike heparin, which requires antithrombin III as a cofactor to exert its anticoagulant effect, hirudin directly and irreversibly binds to thrombin in a 1:1 molar ratio, forming a tight equimolar complex that simultaneously blocks both the active catalytic site and the fibrinogen-binding exosite of the thrombin molecule. This bivalent inhibition strategy distinguishes hirudin from nearly all other anticoagulants. Moreover, hirudin’s small molecular size allows it to access and inactivate clot-bound thrombin—a critical advantage over heparin, which is largely ineffective against thrombin already embedded within a fibrin clot.

The clinical advantages of hirudin over conventional anticoagulants are well-documented in the pharmacological literature. Hirudin does not require antithrombin III as a cofactor, is not inactivated by antiheparin proteins, and has no direct effects on platelets. It is also a surprisingly weak immunogen, with an extremely low propensity to induce antibody formation, making it suitable for repeated administration.

Perhaps most importantly, hirudin offers a solution for patients who cannot tolerate heparin. Heparin-induced thrombocytopenia (HIT)—a life-threatening immune-mediated complication of heparin therapy—affects a significant number of patients. Hirudin does not bind to platelet factor 4, nor does it elicit antibodies that induce platelet activation; thus, it can be safely administered to patients with HIT, for whom it is now regarded as the treatment of choice.

The pharmacodynamic profile of hirudin is also notable for its predictability. Effective anticoagulatory doses can be easily determined, and laboratory monitoring is straightforward—in contrast to the wide inter-patient variability observed with heparin therapy.

The clinical utility of hirudin in cardiovascular disease has been evaluated in several landmark trials. The Thrombolysis in Myocardial Infarction (TIMI) 5 trial, a randomized pilot study of 246 patients with acute myocardial infarction, compared recombinant hirudin against heparin as adjunctive therapy to thrombolysis. Results showed that 61.8% of hirudin-treated patients achieved the primary endpoint (TIMI grade 3 flow without death or reinfarction) compared to 49.4% of heparin-treated patients. More strikingly, the incidence of death or reinfarction during the hospital period was 6.8% in the hirudin group versus 16.7% in the heparin group (p = 0.02). Major spontaneous hemorrhage occurred in only 1.2% of hirudin-treated patients compared to 4.7% of heparin-treated patients.

In the GUSTO IIb trial, involving patients with non–ST segment elevation acute coronary syndrome, hirudin reduced the risk of death or nonfatal myocardial infarction at 24 hours compared to unfractionated heparin (1.3% versus 2.1%, p = 0.001). The OASIS-1 and OASIS-2 trials further confirmed the superior efficacy of hirudin in reducing cardiovascular events in patients with unstable angina and suspected myocardial infarction.

Beyond acute coronary syndromes, a recent systematic review and meta-analysis published in Frontiers in Pharmacology (2025) evaluated 65 randomized controlled trials involving 7,221 patients with coronary heart disease treated with leech-containing herbal medicines. The meta-analysis found that leech-based treatments significantly improved total effective rate (OR = 3.70), electrocardiogram efficacy (OR = 2.58), and hemorheological parameters, while importantly, adverse event rates did not increase compared to conventional treatments. A separate clinical study on unstable angina pectoris reported a total effective rate of 90.62% with hirudin treatment, accompanied by significant reductions in whole blood viscosity, plasma viscosity, and platelet aggregation rates, with low side effects.

Emerging research continues to expand the clinical applications of hirudin. A 2024 study published in Frontiers in Pharmacology investigated recombinant neorudin—a novel anticoagulant drug that is cleaved at the site of thrombus formation to produce hirudin locally. The study demonstrated that hirudin accumulates preferentially within thrombi, achieving higher concentrations inside the clot than in peripheral blood, a distribution pattern that enhances antithrombotic efficacy while potentially minimizing systemic bleeding risk.

With advances in biotechnology, recombinant hirudin (r-hirudin) has become available, produced in yeast or bacterial expression systems. Both natural and recombinant hirudins show almost identical pharmacodynamic and pharmacokinetic properties. However, important differences exist.

Structurally, recombinant hirudin differs from natural hirudin in the sulfation state of the tyrosine residue at position 63. In natural hirudin, this tyrosine is sulfonated to Tyr-SO₃, whereas recombinant hirudin is typically non-sulfonated. While many recombinant variants demonstrate comparable anticoagulant potency to natural hirudin, a study comparing native and recombinant hirudins found that the affinity of native hirudin does not differ significantly from that of recombinant hirudin Lys-47, but distinctly lower affinity for thrombin was observed in other recombinant variants.

Notably, research published in the Chinese Journal of Tissue Engineering Research demonstrated that both natural and recombinant hirudin promote vascular endothelial growth factor (VEGF) expression and improve random skin flap survival rates, but the natural hirudin group showed the greatest VEGF expression, indicating superior angiogenic effects. Furthermore, cell-free synthesized hirudin has shown considerably higher anti-thrombin activity compared to recombinant hirudin produced in bacterial cells. These findings suggest that while recombinant technology has made hirudin more accessible, the natural molecule retains unique structural features that confer optimal biological activity.

The safety of hirudin has been extensively studied. Toxicological evaluations have shown that hirudin lyophilized powder has an oral LD₅₀ > 10.0 g/kg in mice, placing it in the practically non‑toxic category, with no observed mutagenic effects. As a weak immunogen, hirudin administration exhibits no significant side effects, particularly on platelets.

Nevertheless, certain precautions warrant mention. As a potent anticoagulant, hirudin can increase bleeding risk when used at high doses or in combination with other antithrombotic agents. The OASIS-1 study reported a modest increase in moderate bleeding with hirudin treatment (8.8% versus 7.7% with heparin). Additionally, hirudin is predominantly excreted renally, requiring dose adjustment in patients with impaired kidney function. Importantly, no specific antidote for hirudin exists, as it is not neutralized by protamine sulfate.

The therapeutic potential of natural hirudin depends critically on the quality and purity of the source material. Natural leech populations have declined dramatically due to over‑collection and habitat loss, making sustainable, controlled production essential. Factory‑based farming of medicinal leeches under Good Agricultural Practice (GAP) standards addresses this challenge by ensuring consistent quality, traceability, and safety.

Research has demonstrated that medicinal leeches produced through purification cultivation processes—with stringent controls over farming environment, water quality, feeding, sterilization, and microbial testing—pass multiple batches of microbial tests and meet medical standards. In clinical applications involving over 200 cases, no serious allergies or pathogenic microbial infections were reported. This high level of safety is unattainable with wild‑caught leeches, which may carry environmental pathogens and exhibit variable anticoagulant potency.

Our GAP‑certified facility specializes in the factory farming of Hirudo nipponia (Asian medicinal leech), employing advanced aquaculture techniques to produce leeches with consistent, high‑quality hirudin content. Every batch undergoes rigorous quality control to ensure microbiological safety and biological activity, providing the medical community with a reliable source of natural hirudin for cardiovascular health applications.

The scientific literature overwhelmingly supports the value of hirudin as a potent, specific, and well‑tolerated anticoagulant. From its elegant bivalent inhibition of thrombin to its demonstrated clinical efficacy in acute coronary syndromes and coronary heart disease, hirudin represents a significant advancement in cardiovascular pharmacotherapy. While recombinant technologies have expanded access to this remarkable molecule, natural hirudin retains unique structural features that contribute to optimal biological activity.

For healthcare professionals and patients seeking scientifically validated alternatives for cardiovascular health management, natural hirudin—produced under rigorous quality standards—offers a compelling option grounded in decades of research and clinical experience. As the global burden of thrombotic diseases continues to rise, the therapeutic value of this ancient natural compound has never been more relevant.

1. Markwardt F, et al. Antithrombin effects of native and recombinant hirudins. Biomedica Biochimica Acta. 1990;49(2-3):399-404. PMID: 2271010.

2. Monreal M, Costa J, Salva P. Pharmacological properties of hirudin and its derivatives. Potential clinical advantages over heparin. Drugs & Aging. 1996;8(3):171-182. PMID: 8720743.

3. Hirudin. ScienceDirect Topics: Pharmacology, Toxicology and Pharmaceutical Science. 

4. Cannon CP, McCabe CH, Henry TD, et al. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial. Journal of the American College of Cardiology. 1994;23(5):993-1003.

5. Hirudin, a new therapeutic tool? Blut. 1991;63(2):67-69.

6. Li Q, Liu Y, Ren B, et al. Recombinant neorudin and its active metabolite hirudin: the fate in vivo of a novel anticoagulant drug. Frontiers in Pharmacology. 2024;15:1443475.

7. Zhao Z, et al. The clinical efficacy of herbal medicines containing leeches in the treatment of coronary heart disease: a systematic review and meta-analysis. Frontiers in Pharmacology. 2025;16:1643611. PMID: 41181591.

8. He Q, Huang JJ, Cai JM, et al. Clinical observation of hirudin in the treatment of unstable angina pectoris. Practical Journal of Integrated Chinese and Western Medicine in Clinical Practice. 2008;8(3):3-4.

9. Guo YX, Yin GQ, Li JQ, Xiao H. Effect of natural and recombinant hirudin on vascular endothelial cell growth factor in random skin flap congestion models. Chinese Journal of Tissue Engineering Research. 2011;15(7):1245-1248.

10. Chen C, Ren Q, Jumuddin FA. Low-Cost Purification Cultivation Process For Medical "Hirudinaria Manillensis". Journal of Animal & Zoo. 2022;43(S1).

11. Abstract 4139014: Building Nucleic Acid-Based Hirudins: Potent, Selective, and Reversible Protease Inhibitors. Circulation. 2024;150(Suppl_1).

12. Hirudin. ScienceDirect Topics: Neuroscience.